Notably, the present study first identified HME as a potent blocker for STAT3 signaling in bladder cancer cells, as HME markedly inhibited both constitutive and IL-6-inducible STAT3 activation (Figure 3A,B). Here, STAT3 is linked to urinary bladder carcinoma.